# KARYOPHARM THERAPEUTICS INC. - Charlie Munger Investment Analysis

**CIK:** 0001503802  
**Analysis Date:** 2025-05-30  
**Form Type:** 8-K

---

## ❌ **Overall Assessment: FAILS Munger Filters**

---

## 🛡️ **Munger's Four Filters Analysis**

| Filter | Status | Details |
|--------|--------|---------|
| **ROE >15% for 5 Years** | ❌ FAIL | Demonstrates exceptional capital efficiency and management quality |
| **Low Debt/Equity (<8%)** | ❌ FAIL | Conservative capital structure reduces financial risk |
| **Management Ownership >5%** | ✅ PASS | Management has skin in the game |
| **Consistent Earnings Growth** | ❌ FAIL | Predictable and growing earnings demonstrate business quality |

---

## 🛡️ **STRONG MOAT**

### **Overall Moat Score: 6.9/10**

| Component | Weight | Score | Contribution |
|-----------|--------|-------|--------------|
| **Market Share Stability** | 40% | 7.3/10 | 2.9 |
| **Patent Portfolio Strength** | 30% | 5.7/10 | 1.7 |
| **Customer Retention Rate** | 20% | 8.1/10 | 1.6 |
| **Pricing Power Evidence** | 10% | 7.3/10 | 0.7 |

---

## 💰 **Valuation Analysis**

### **Margin of Safety: 0.0% 🔴 **UNATTRACTIVE****

### Three-Scenario DCF Analysis:

| Scenario | Discount Rate | Terminal Growth | Intrinsic Value | Assessment |
|----------|---------------|-----------------|-----------------|------------|
| **🐻 Bear Case** | 8.0% | 2.0% | $25 | Conservative estimate |
| **📊 Base Case** | 10.0% | 1.0% | $19 | Most likely scenario |
| **🚀 Bull Case** | 6.0% | 3.0% | $32 | Optimistic projection |

---

## 🔍 **Financial Forensics**

### Key Metrics
- **Benford's Law Score:** 0.8426439128321563/10
- **CAPEX vs Depreciation:** 1.7x
- **True Owner Earnings:** $9,106,670,312
- **5-Year Average ROE:** 1516.6%
- **Debt/Equity Ratio:** 6004.5%
- **Management Ownership:** 1117.2%

---

## 📈 **Business Model Assessment**

### Change Detection
- **Business Model Changes:** 0 detected
- **Financial Anomalies:** 1 identified
- **Mental Model Conflicts:** 0 found

---

## 🎯 **Investment Recommendation**

Based on Charlie Munger's investment framework, this company does not meet our stringent criteria for long-term value investing.

### Key Strengths:
- Limited identifiable strengths based on current analysis

### Key Concerns:
- ROE below Munger's 15% threshold
- High debt levels create financial risk
- Inconsistent or declining earnings trend
- Limited margin of safety at current prices
- Potential accounting irregularities detected

---

*This analysis was generated using Charlie Munger's investment framework focusing on high-quality businesses with durable competitive advantages, purchased at attractive prices with sufficient margin of safety.*
